Secondary effects of antipsychotics: women at greater risk than men.
about
Effect of atypical antipsychotics on fetal growth: is the placenta involved?Changes in body weight and psychotropic drugs: a systematic synthesis of the literatureThe cross-sectional GRAS sample: a comprehensive phenotypical data collection of schizophrenic patients.Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in ratsBipolar in Women: Any Gender-based Difference?Randomized controlled trial comparing changes in serum prolactin and weight among female patients with first-episode schizophrenia over 12 months of treatment with risperidone or quetiapineA double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.Low rate of obesity among psychiatric inpatients in Indonesia.Metabolic Syndrome in South African Patients with Severe Mental Illness: Prevalence and Associated Risk Factors.Brain stem as a target site for the metabolic side effects of olanzapinePredictors of outcome in brief cognitive behavior therapy for schizophrenia.Sex differences in the psychopharmacological treatment of depression.Comparison of Sexual Function and Hormonal Parameters Between Mood Stabilizer Treatment Modalities in Bipolar Disorder.Sexual dimorphism in schizophrenia: is there a need for gender-based protocols?More than just milk: a review of prolactin's impact on the treatment of anorexia nervosa.Women and psychosis.Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders.Neural changes induced by antipsychotic administration in adolescence: A review of studies in laboratory rodents.Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on BDNF stimulators loxapine and amitriptyline.How gender affects the pharmacotherapeutic approach to treating psychosis - a systematic review.Pharmacokinetic patterns of risperidone-associated adverse drug reactions.Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model.Gender differences in mood stabilizer medications prescribed to Veterans with serious mental illness.Gender differences in antipsychotics prescribed to veterans with serious mental illness.Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes.Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers.Clinical Management of Antipsychotic-Induced Hyperprolactinemia.Adaptation of the Texas Implementation Medication Algorithm for Bipolar Disorder in Adult Female Offenders.Preventing breast cancer in women with schizophrenia.Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions.Women who suffer from schizophrenia: Critical issues
P2860
Q27012948-16EB2776-BA7F-4B3F-BAC4-ABA19BAA377DQ28728401-75C8154B-4761-4D11-88E7-AE6BB5F44B56Q33743615-AA156B87-620C-4B28-8A5A-0381A6D59774Q33765864-213282CC-BF63-445F-8BD5-9E262465C3D2Q33772103-93445232-B149-4D07-BA48-6759D368E69AQ33995754-3FB4D196-7D0B-4871-B5AE-00284E07700DQ35156543-471520F2-D7FD-4877-905F-2DB48D7C82BBQ35506750-ADD76C82-2941-45AE-BBCA-1F376665B780Q35925059-82475F19-35E8-4A79-A6C7-CE4D511D567BQ36729872-DA150110-22E3-49C9-A982-772353BFFF1FQ37310206-C8A2EAC0-A8C2-45BB-B812-8A0F8E5FD28CQ37618539-2FDE88DF-7AF3-4CF9-94FF-82CCB34DFF3BQ37703967-AFC41FCB-DFFB-4F20-8BE2-06595D90584FQ37896624-A069630C-A0BA-4004-9735-D8DD2B2E698EQ37903006-36326FC7-48D1-4B5C-8E5A-3A1C5ADCF3F3Q37989182-9DF95ED3-6AD1-47E5-9383-725418C929F2Q38717462-0EB7A969-B556-4277-80EB-722F466D4EA9Q38815462-16C9764D-392C-44A5-BCA5-991F9C8902FEQ38842111-6BDED14A-4E94-4F5A-ACC9-503D34BE3DD6Q38881791-CC654E25-A586-4CCF-B17F-240138A1B285Q38994958-07595CB4-9F38-4E1A-A7E7-83BC76AD04C1Q39633628-9EEB4401-9CD3-4BED-974B-7B170D5CD08FQ40320924-C2F970EA-F8C3-491E-8E92-65CDF0121724Q40549171-828D7E96-0413-4C33-99D7-183F40B7CDF9Q40982860-C2EE5CFF-1CE8-4F28-BDC8-AF0326BEF21EQ47165661-A9363F0D-1FC7-46EE-BE3F-E8519AE69E72Q47998134-810B6EDA-F9F9-4B7C-AF9D-36C67EEA46FDQ50593929-20993E6D-7940-4F1B-A42C-FCD6E2A69CDEQ50939451-BC3E5916-BDFC-4641-ACC1-27FEB8487C77Q51832889-D1424E29-A5B5-44C5-91DF-283538BD868BQ54978736-CC8F527C-2263-4D8D-9B0C-3138C32AB5FCQ58695706-82C12DFB-C53A-422C-B690-729E3B5B2C51
P2860
Secondary effects of antipsychotics: women at greater risk than men.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Secondary effects of antipsychotics: women at greater risk than men.
@en
Secondary effects of antipsychotics: women at greater risk than men.
@nl
type
label
Secondary effects of antipsychotics: women at greater risk than men.
@en
Secondary effects of antipsychotics: women at greater risk than men.
@nl
prefLabel
Secondary effects of antipsychotics: women at greater risk than men.
@en
Secondary effects of antipsychotics: women at greater risk than men.
@nl
P2860
P356
P1476
Secondary effects of antipsychotics: women at greater risk than men.
@en
P2093
Mary V Seeman
P2860
P304
P356
10.1093/SCHBUL/SBN023
P407
P577
2008-04-09T00:00:00Z